Lexaria Bioscience Reports Positive Interim Results in GLP-1 Study, Showing Reduced Side Effects
TL;DR
Lexaria Bioscience Corp.'s DehydraTECH-semaglutide shows a 36.5% reduction in side effects compared to Rybelsus®, offering a competitive edge in GLP-1 treatments.
Lexaria's study demonstrates DehydraTECH-semaglutide's mechanism reduces gastrointestinal side effects by 43.5% and overall side effects by 36.5% versus Rybelsus® in an 8-week interim analysis.
DehydraTECH-semaglutide's reduced side effects could improve patient adherence to treatment, enhancing quality of life for millions managing diabetes and obesity.
Lexaria's innovative DehydraTECH technology not only cuts side effects significantly but also hints at a future where oral GLP-1 treatments surpass injectables in safety.
Found this article helpful?
Share it with your network and spread the knowledge!
Lexaria Bioscience Corp. has announced promising interim results from its phase 1b study, GLP-1-H24-4, focusing on the DehydraTECH-semaglutide formulation. The study, currently underway in Australia, has shown a 36.5% reduction in overall side effects and a 43.5% decrease in gastrointestinal adverse events compared to Rybelsus®, the only approved oral-based GLP-1 medication. These findings suggest that DehydraTECH-semaglutide could offer a safer and more tolerable option for patients, potentially leading to higher adherence rates to treatment protocols.
The study's interim results after 8 weeks of treatment highlight the safety and tolerability of DehydraTECH-GLP-1 arms, with notable reductions in adverse events. Specifically, 79.2% of patients in the DHT-semaglutide arm experienced at least one adverse event, compared to 100% in the Rybelsus® control arm. This represents a significant improvement in patient comfort and could encourage more individuals to continue their treatment without premature discontinuation due to unwanted side effects.
Comparisons with historical data from Novo Nordisk's STEP and Pioneer studies further underscore the potential benefits of DehydraTECH-semaglutide. The interim results align with the primary study endpoint, demonstrating the formulation's superiority in reducing side effects. Additionally, the study's findings on body weight and HbA1c levels, though preliminary, suggest that DHT-semaglutide performs comparably to Rybelsus® in terms of efficacy, with the full 12-week data expected to provide more definitive insights.
The implications of these findings are significant for the millions of people currently on GLP-1 medications, offering hope for a treatment option with fewer side effects. The study remains on schedule, with final results anticipated by the end of calendar-2025. Lexaria Bioscience Corp.'s innovative approach to drug delivery through its DehydraTECH technology continues to show promise in improving the bioavailability and tolerability of medications, potentially transforming treatment protocols for a wide range of conditions.
Curated from NewMediaWire
